Development of a novel transcription factors-related prognostic signature for serous ovarian cancer

Abstract Growing evidence suggest that transcription factors (TFs) play vital roles in serous ovarian cancer (SOC). In the present study, TFs mRNA expression profiles of 564 SOC subjects in the TCGA database, and 70 SOC subjects in the GEO database were screened. A 17-TFs related prognostic signatur...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	He Li, Nayiyuan Wu, Zhao-Yi Liu, Yong-Chang Chen, Quan Cheng, Jing Wang
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/75cdafb74d0245c0873fe2764ea5b56a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:75cdafb74d0245c0873fe2764ea5b56a
record_format	dspace
spelling	oai:doaj.org-article:75cdafb74d0245c0873fe2764ea5b56a2021-12-02T13:27:04ZDevelopment of a novel transcription factors-related prognostic signature for serous ovarian cancer10.1038/s41598-021-86294-z2045-2322https://doaj.org/article/75cdafb74d0245c0873fe2764ea5b56a2021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-86294-zhttps://doaj.org/toc/2045-2322Abstract Growing evidence suggest that transcription factors (TFs) play vital roles in serous ovarian cancer (SOC). In the present study, TFs mRNA expression profiles of 564 SOC subjects in the TCGA database, and 70 SOC subjects in the GEO database were screened. A 17-TFs related prognostic signature was constructed using lasso cox regression and validated in the TCGA and GEO cohorts. Consensus clustering analysis was applied to establish a cluster model. The 17-TFs related prognostic signature, risk score and cluster models were effective at accurately distinguishing the overall survival of SOC. Analysis of genomic alterations were used to elaborate on the association between the 17-TFs related prognostic signature and genomic aberrations. The GSEA assay results suggested that there was a significant difference in the inflammatory and immune response pathways between the high-risk and low-risk score groups. The potential immune infiltration, immunotherapy, and chemotherapy responses were analyzed due to the significant difference in the regulation of lymphocyte migration and T cell-mediated cytotoxicity between the two groups. The results indicated that patients with low-risk score were more likely to respond anti-PD-1, etoposide, paclitaxel, and veliparib but not to gemcitabine, doxorubicin, docetaxel, and cisplatin. Also, the prognostic nomogram model revealed that the risk score was a good prognostic indicator for SOC patients. In conclusion, we explored the prognostic values of TFs in SOC and developed a 17-TFs related prognostic signature to predict the survival of SOC patients.He LiNayiyuan WuZhao-Yi LiuYong-Chang ChenQuan ChengJing WangNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-14 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q He Li Nayiyuan Wu Zhao-Yi Liu Yong-Chang Chen Quan Cheng Jing Wang Development of a novel transcription factors-related prognostic signature for serous ovarian cancer
description	Abstract Growing evidence suggest that transcription factors (TFs) play vital roles in serous ovarian cancer (SOC). In the present study, TFs mRNA expression profiles of 564 SOC subjects in the TCGA database, and 70 SOC subjects in the GEO database were screened. A 17-TFs related prognostic signature was constructed using lasso cox regression and validated in the TCGA and GEO cohorts. Consensus clustering analysis was applied to establish a cluster model. The 17-TFs related prognostic signature, risk score and cluster models were effective at accurately distinguishing the overall survival of SOC. Analysis of genomic alterations were used to elaborate on the association between the 17-TFs related prognostic signature and genomic aberrations. The GSEA assay results suggested that there was a significant difference in the inflammatory and immune response pathways between the high-risk and low-risk score groups. The potential immune infiltration, immunotherapy, and chemotherapy responses were analyzed due to the significant difference in the regulation of lymphocyte migration and T cell-mediated cytotoxicity between the two groups. The results indicated that patients with low-risk score were more likely to respond anti-PD-1, etoposide, paclitaxel, and veliparib but not to gemcitabine, doxorubicin, docetaxel, and cisplatin. Also, the prognostic nomogram model revealed that the risk score was a good prognostic indicator for SOC patients. In conclusion, we explored the prognostic values of TFs in SOC and developed a 17-TFs related prognostic signature to predict the survival of SOC patients.
format	article
author	He Li Nayiyuan Wu Zhao-Yi Liu Yong-Chang Chen Quan Cheng Jing Wang
author_facet	He Li Nayiyuan Wu Zhao-Yi Liu Yong-Chang Chen Quan Cheng Jing Wang
author_sort	He Li
title	Development of a novel transcription factors-related prognostic signature for serous ovarian cancer
title_short	Development of a novel transcription factors-related prognostic signature for serous ovarian cancer
title_full	Development of a novel transcription factors-related prognostic signature for serous ovarian cancer
title_fullStr	Development of a novel transcription factors-related prognostic signature for serous ovarian cancer
title_full_unstemmed	Development of a novel transcription factors-related prognostic signature for serous ovarian cancer
title_sort	development of a novel transcription factors-related prognostic signature for serous ovarian cancer
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/75cdafb74d0245c0873fe2764ea5b56a
work_keys_str_mv	AT heli developmentofanoveltranscriptionfactorsrelatedprognosticsignatureforserousovariancancer AT nayiyuanwu developmentofanoveltranscriptionfactorsrelatedprognosticsignatureforserousovariancancer AT zhaoyiliu developmentofanoveltranscriptionfactorsrelatedprognosticsignatureforserousovariancancer AT yongchangchen developmentofanoveltranscriptionfactorsrelatedprognosticsignatureforserousovariancancer AT quancheng developmentofanoveltranscriptionfactorsrelatedprognosticsignatureforserousovariancancer AT jingwang developmentofanoveltranscriptionfactorsrelatedprognosticsignatureforserousovariancancer
_version_	1718393039133605888

Development of a novel transcription factors-related prognostic signature for serous ovarian cancer

Ejemplares similares